Non-High-Density Lipoprotein Cholesterol
NON-HDL
Description
"Non-High-Density Lipoprotein (Non-HDL) Cholesterol" test measures all potentially harmful cholesterol particles, including LDL and VLDL, to assess cardiovascular risk more accurately than LDL alone. Doctors use this test to evaluate heart disease risk in people with diabetes, obesity, or metabolic syndrome. Elevated levels suggest increased likelihood of arterial plaque buildup. Results guide personalized treatment through lifestyle changes, medications, or further testing. Regular monitoring of non-HDL cholesterol helps protect long-term cardiovascular health and prevent future complications.
Category
Lipids, Proteins
Procedure
Invasive
Sample Type
Blood – Serum
Units
Millimoles Per Liter
Procedure Category
Blood Draw
Test Group
Complete Lipid Group, Complete Cardiovascular Group, Cardio Risk Group
Test Group Description
Cardio Risk Group: This group focuses on assessing various markers associated with cardiovascular health and risk factors, aiding in the early detection and management of cardiovascular diseases. Complete Cardiovascular Group: This group contains comprehensive tests for an extensive evaluation of cardiovascular health, providing thorough insights into heart-related conditions beyond basic assessments. Complete Lipid Group: Extensive tests offer a comprehensive evaluation of lipid levels, providing detailed insights into cholesterol and triglyceride profiles and their implications for cardiovascular health.
Optimal Range
For All Individuals:
Conventional Unit: 0.00–2.60 mmol/L
SI Unit: 0.00–2.60 mmol/L
Normal Range
For All Individuals:
Conventional Unit: 0.00–3.37 mmol/L
SI Unit: 0.00–3.37 mmol/L
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Chronic kidney disease
Chronic liver disease
Dyslipidemia (Abnormal levels of lipids in the blood)
Excessive transfat intake
Familial hypercholesterolemia (Genetic disorder causing high cholesterol levels)
Hypothyroidism (Underactive thyroid gland)
Metaboli...
Key Reasons For Testing
Comprehensive Risk Assessment: Provides a complete evaluation of cardiovascular risk by including all atherogenic lipoproteins.
Atherosclerosis Prediction: Acts as a strong predictor for atherosclerosis and its progression, aiding in early risk identification.
Therapy Monitoring: Tracks changes in non-HDL cholesterol to assess treatment response and optimize strategies.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
[2] Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98(10):1363-1368.
[3] Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009;55(5):888-894.
[4] Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361(9359):777-780.
[5] Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375-3383.
[6] Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326-333.
[7] Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study. Circulation. 1997;95(1):69-75.
[8] Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53(4):316-322.
[9] Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic lipoprotein particle size and number, independent of lipids, predict incident cardiovascular disease. Circulation. 2011;124(8):934-941.
[10] Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002-3009.
[11] Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55(1):35-41.
[12] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25).
[13] Assmann G, Schulte H, Cullen P. New and classical risk factors—the Münster Heart Study (PROCAM). Eur J Med Res. 1997;2(6):237-242.